Microcap Ledger PDS Biotechnology Corp $PDSB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Princeton, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 55,971,338 [10-Q 2026-08-13]
What the company doesAI summary of filing
PDS Biotechnology Corp is a clinical-stage immunotherapy company developing targeted cancer and infectious disease vaccines. The company's primary oncology pipeline is based on its Versamune T cell activator platform combined with various tumor antigens, and its IL-12 antibody drug conjugate PDS01ADC; these programs are in Phase 2 and Phase 3 clinical trials treating HPV-related cancers, cervical cancer, prostate cancer, breast cancer, and other solid tumors. The company is also developing Infectimune, a T cell-activator platform for infectious disease vaccines, including a universal influenza vaccine candidate. PDS Biotech is pre-revenue and generates no product sales, focusing instead on advancing clinical trials and research collaborations with institutions including the National Cancer Institute. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$17.10M | −$7.16M | $5.60M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$34.50M | −$27.75M | $26.71M | [DEF 14A 2026-06-26] |
| FY ended Dec 2024 | — | −$37.61M | −$35.03M | $41.69M | [DEF 14A 2026-06-26] |
- Quarterly cash burn
- −$3.58M
- Cash runway Estimate
- ~4.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 37,409,137 | [10-Q 2024-11-14] |
| 2025-03-20 | 45,395,851 | [10-K 2025-03-27] |
| 2025-05-07 | 45,710,000 | [10-Q 2025-05-14] |
| 2025-08-06 | 46,633,362 | [10-Q 2025-08-13] |
| 2025-11-06 | 48,980,307 | [10-Q 2025-11-13] |
| 2026-03-23 | 55,815,653 | [10-K/A 2026-04-28] |
| 2026-05-07 | 55,815,653 | [10-Q 2026-05-14] |
| 2026-08-06 | 55,971,338 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-07-10; declared effective 2026-07-21 [S-3 2026-07-10]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-31] |
| 2026-03-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Other events |
| 2026-09-22 | 8-K | Other events |
| 2026-09-21 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-21 | 8-K | Other events |
| 2026-09-14 | 8-K | Material agreement terminated; Director or officer change; Regulation FD disclosure |
| 2026-09-08 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-09-04 | 8-K | Material agreement entered; New financial obligation |
| 2026-08-25 | 8-K | Exit or disposal costs; Director or officer change |
| 2026-08-19 | 8-K | Director or officer change |
| 2026-08-14 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
Alerts for $PDSB
Email me when PDS Biotechnology Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.